Xellia Pharmaceuticals, a specialty pharmaceutical company focusing on providing important anti-infective treatments, announces the expansion of its Raleigh (North Carolina, USA) site to enable the relocation of its North American headquarters from Grayslake, Illinois.
One year on from its acquisition of the Raleigh plant from Fresenius Kabi, Xellia has taken on new premises adjacent to its dedicated lyophilized (freeze-dried) vial manufacturing facility.
The result is the combination of the company’s North American commercial function with the manufacturing facility into one location, forming the new headquarters for the territory. Staff based at the Grayslake site have begun a phased relocation.
Carl-Åke Carlsson, CEO, Xellia, said: “The US is a key market for Xellia and the expansion is part of our long-term growth strategy and commitment to manufacturing in the US, for our North American customers. Consolidating our state-of-the-art production facility with our commercial headquarters will enable us to better serve our many customers – both with respect to proximity and working relationship. We are building a stronger, more connected US operation.”
Xellia has more than 100 years of pharmaceutical industry experience and specializes in difficult-to-manufacture and develop anti-infective products. The company is increasingly moving on from its origins as a manufacturer of active pharmaceutical ingredients (APIs) to better serve its global customer base of more than 500 pharmaceutical companies by supplying the finished dosage form (FDF) of its drugs.